References
- Clegg R. J., Middleton B., Bell G. D., White D. A. The mechanism of cyclic monoterpene inhibition of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase in vivo in the rat. Journal of Biological Chemistry 1982; 257: 2294–2299
- Fry J. R. Preparation of mammalian hepatocytes. Methods in Enzymology 1981; 77: 130
- Heffron F. Ph.D. thesis. The effect of cyclandelate on cholesterol esterification in rat liver and cultured J77 macrophages. University of Nottingham, UK 1988
- Heffron F., White D. A., Middleton B. The consequences of ACAT inhibition by cyclandelate on LDL metabolism by J774 macrophages. Biological Society Transactions 1989; 17: 127
- Middleton A., White D. A., Bell G. D., Middleton B. The in vivo inhibition of hepatic lipogenesis in the rat by cyclandelate. Biological Pharmacology 1983 b; 32: 3079–3083
- Middleton B., Cacciaguerra F., White D. A. Cyclandelate: An inhibitor of cholesterol esterification. Drugs 1987; 33: 75–79, (Suppl. 2)
- Middleton B., Middleton A., Miciak A., White D. A., Bell G. D. The inhibition of hepatic S-3-hydroxy-3-methylglutaryl-CoA reductase by 3,3,5-trimethylcyclohexanol and its mandelic acid ester, cyclandelate. Biological Pharmacology 1983 a; 32: 649–651
- Middleton B., Middleton A., White D. A., Bell G. D. Dietary cyclandelate decreases pre-established atherosclerosis in the rabbit. Atherosclerosis 1984; 171: 171–178
- Reichl D., Miller M. E. The anatomy and physiology of reverse cholesterol transport. Clinical Science 1986; 70: 221–231
- Timmerman H. Calcium modulation and Clinical effect: profile of cyclandelate. Drugs 1987; 33: 1–4, (Suppl. 2)